Multiple sclerosis (MS): investigational treatments
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Multiple sclerosis (MS): investigational treatments. Amiselimod, Laquinimod, Ceralifimod, GSK2018682. Fully referenced neurology checklist.
Sphingosin-1-phosphate receptor modulators
- Amiselimod
- Laquinimod
- Ceralifimod
- GSK2018682
Rituximab
Locked: subscribe to see this section.
Ibudilast
Locked: subscribe to see this section.
Clemastine fumarate
Locked: subscribe to see this section.
Minocycline
Locked: subscribe to see this section.
Simvastatin
Locked: subscribe to see this section.
Emerging cell-based therapies
Locked: subscribe to see this section.
Tyrosine kinase (TK) inhibitors
Locked: subscribe to see this section.
Other potential agents
Locked: subscribe to see this section.
References
- Radick L, Mehr SR. The latest innovations in the drug pipeline for multiple sclerosis. Am Health Drug Benefits 2015; 8:448-453.
- Chaudhry BZ, Cohen JA, Conway DS. Sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis. Neurotherapeutics 2017; 14:859-873.
- Subei AM, Cohen JA. Sphingosine 1-phosphate receptor modulators in multiple sclerosis. CNS Drugs 2015; 29:565-575.Cohen JA, Arnold DL, Comi G, et al; RADIANCE Study Group. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2016; 15:373-381.
- Kappos L, Arnold DL, Bar-Or A, et al. Two-year results from a phase 2 extension study of oral amiselimod in relapsing multiple sclerosis. Mult Scler 2017; 1:1352458517728343.
- Kappos L, Arnold DL, Bar-Or A, et al. Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 2016; 15:1148-1159.
- And 37 more. Subscribe to see the full list
